Home › NDC Lookup › RxCUI directory › RxCUI 1859498

Eltrombopag 25 MG Powder for Oral Suspension — RxCUI 1859498

RxNorm drug concept · Semantic clinical drug
RxCUI 1859498 Semantic clinical drug · SCD ● Current RxNorm concept 8 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1859498
Official nameEltrombopag 25 MG Powder for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aseltrombopag (as eltrombopag olamine) 25 MG Powder for Oral Suspension
FDA products mapped8
Package NDCs mapped9
Reported Medicaid activity (SDUD)8,339 prescriptions · 35 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Eltrombopag: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It raises low platelet counts in persistent or chronic ITP and in chronic hepatitis C, so hepatitis C treatment with interferon can proceed. It also treats severe aplastic anemia....
  • Take it by mouth, usually once a day, on an empty stomach or with a low-calcium meal. Keep it 2 hours before or 4 hours after antacids, dairy, and mineral supplements. Follow your...
  • Calcium and other minerals bind eltrombopag and keep your body from absorbing it. A high-calcium meal cut absorption a lot in studies. Spacing them out keeps the medicine working.
  • Common ones include nausea, diarrhea, headache, tiredness, fever, and cough. Liver blood tests can also rise, which is why they are checked often.
📖 Read our full Eltrombopag guide →

🕸️ Concept Web — How Eltrombopag 25 MG Powder for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Eltrombopag 25 MG Powder for Oral Suspension RxCUI 1859498

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Eltrombopag 711942
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Promacta 825422
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Eltrombopag Powder for Oral Suspension 1665882
    • Eltrombopag Oral Powder Product 1665877
    • Eltrombopag Oral Product 1161299
    • Eltrombopag Powder for Oral Suspension [Promacta] 1859499
    • Promacta Oral Powder Product 1859500
    • Promacta Oral Product 1181288
    • Powder for Oral Suspension 1540456
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Eltrombopag 25 MG SCDC · 825419
  • Eltrombopag Powder for Oral Suspension SCDF · 1665882
  • Eltrombopag Oral Powder Product SCDG · 1665877
  • Eltrombopag Oral Product SCDG · 1161299

Brand-Name Concepts

  • Eltrombopag 25 MG Powder for Oral Suspension [Promacta] SBD · 1859501
  • Eltrombopag 25 MG [Promacta] SBDC · 825423
  • Eltrombopag Powder for Oral Suspension [Promacta] SBDF · 1859499
  • Promacta Oral Powder Product SBDG · 1859500
  • Promacta Oral Product SBDG · 1181288
  • Promacta BN · 825422

📦 FDA Products & Package NDCs

8 products · 9 package NDCs
9 package NDCs map to RxCUI 1859498 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-0684-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0684-15) PROMACTA Novartis Pharmaceuticals Corporation 2016-08-22
00078-0685-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0685-15) PROMACTA Novartis Pharmaceuticals Corporation 2016-05-24
00078-0686-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0686-15) PROMACTA Novartis Pharmaceuticals Corporation 2016-04-07
00078-0686-55 14 TABLET, FILM COATED in 1 BOTTLE (0078-0686-55) PROMACTA Novartis Pharmaceuticals Corporation 2020-01-21
00078-0687-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0687-15) PROMACTA Novartis Pharmaceuticals Corporation 2016-04-01
00078-0697-61 1 CARTON in 1 KIT (0078-0697-61) / 30 PACKET in 1 CARTON (0... PROMACTA Novartis Pharmaceuticals Corporation 2020-03-27
00078-0972-61 1 CARTON in 1 KIT (0078-0972-61) / 30 PACKET in 1 CARTON (0... PROMACTA Novartis Pharmaceuticals Corporation 2018-09-27
31722-0300-32 1 CARTON in 1 KIT (31722-300-32) / 30 PACKET in 1 CARTON (3... Eltrombopag Camber Pharmaceuticals, Inc. 2025-05-13
31722-0301-32 1 CARTON in 1 KIT (31722-301-32) / 30 PACKET in 1 CARTON (3... Eltrombopag Camber Pharmaceuticals, Inc. 2025-05-13
Observed labelers: Novartis Pharmaceuticals Corporation (7) · Camber Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.